TransMedics Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $TMDX in the last 7 days.
No SEC Form 4 filings for $TMDX in the last 30 days.
See all $TMDX insider activity →TransMedics chose Gogo's Galileo HDX for its 22 aircraft fleet to monitor organs during transport. Installation is set for completion by 2027, with plans to expand to Europe in 2028. Gogo's system uses Eutelsat OneWeb's network for connectivity. TransMedics cited Gogo's performance, security, and monitoring capabilities as key factors. Gogo provides aviation and military connectivity solutions.
Analysts updated ratings for healthcare companies. TD Cowen maintained a Buy rating on TransMedics Group (TMDX) with a $120 target. Regeneron (REGN) was kept at Hold by Leerink Partners. Oppenheimer maintained a Buy rating on Tarsus Pharmaceuticals (TARS) with a $100 target. All have consensus ratings and price targets.
TransMedics Group (TMDX) Director David Weill bought 1,336 shares on Sept. 11, 2026, at an average price of $81.63, increasing his stake to 16,392 shares. The company, which focuses on organ transplant technology, has a market cap of $2.7B and TTM revenue of $668.5M. TMDX stock has seen a one-year return of -30%.
Recent TMDX coverage spans financial news, earnings and corporate actions.
TransMedics chose Gogo's Galileo HDX for its 22 aircraft fleet to monitor organs during transport. Installation is set for completion by 2027, with plans to expand to Europe in 2028. Gogo's system uses Eutelsat OneWeb's network for connectivity. TransMedics cited Gogo's performance, security, and monitoring capabilities as key factors. Gogo provides aviation and military connectivity solutions.
Buy rating with a higher price target may support modest upside.
Small insider purchase may signal confidence but limited market impact.
The CFO change may signal strategic shifts and the guidance reaffirmation supports current valuation expectations.
Earnings miss on EPS may pressure the stock despite revenue growth.
AlphAI scores every news story that mentions TMDX with an AI model for sentiment and relevance, and aggregates insider trades from TransMedics Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TransMedics chose Gogo's Galileo HDX for its 22 aircraft fleet to monitor organs during transport. Installation is set for completion by 2027, with plans to expand to Europe in 2028. Gogo's system uses Eutelsat OneWeb's network for connectivity. TransMedics cited Gogo's performance, security, and monitoring capabilities as key factors. Gogo provides aviation and military connectivity solutions.
2 min readAnalysts updated ratings for healthcare companies. TD Cowen maintained a Buy rating on TransMedics Group (TMDX) with a $120 target. Regeneron (REGN) was kept at Hold by Leerink Partners. Oppenheimer maintained a Buy rating on Tarsus Pharmaceuticals (TARS) with a $100 target. All have consensus ratings and price targets.
2 min readTransMedics Group (TMDX) Director David Weill bought 1,336 shares on Sept. 11, 2026, at an average price of $81.63, increasing his stake to 16,392 shares. The company, which focuses on organ transplant technology, has a market cap of $2.7B and TTM revenue of $668.5M. TMDX stock has seen a one-year return of -30%.
2 min readTransMedics Group (TMDX) appointed Fernando Araujo as CFO and reaffirmed its 2026 revenue guidance of $737M-$757M. The stock has seen volatility, down 7.9% in the past month but up 18.2% over 90 days. Analysts estimate a fair value of $97.30, suggesting a 10.3% undervaluation. Expansion into new organ types and product launches could drive growth, but risks include international expansion and regulatory support.
2 min readTransMedics Group (TMDX) and SoFi Technologies (SOFI) have seen significant stock declines. TMDX's revenue grew 21% YoY to $189.9M, but profits fell 52%. SOFI's revenue rose 43% to $1.2B, with net income up 61%. Both face near-term challenges but are seen as long-term opportunities.
3 min readWeill David purchased 1,336 shares of TransMedics Group, Inc. (TMDX) at $81.63 ($0.11M total) on 2026-09-11.
1 min readTransMedics (TMDX) named Fernando Araujo as CFO, effective September 21, 2026. Araujo has 20+ years of finance experience in healthcare, industrial, and energy sectors. The company reiterated its 2026 revenue guidance of $737M-$757M, a 22-25% YoY growth. Araujo will support TransMedics' global growth, while Gerardo Hernandez transitions to a strategic advisory role for Latin America expansion.
2 min readTransMedics Group, Inc. (TMDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook Andover, Mass. – September 10, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for trans
2 min readTransMedics (NASDAQ: TMDX) shares fell about 8% after its Q2 results. The company reported 21% sales growth, but adjusted net income dropped from $35M in Q2 last year to $16M this year, below expectations. Management said about $19M of the change reflected spending on a next-gen kidney OCS, clinical programs, and a manufacturing plant in Italy.
4 min readTransMedics Group (Nasdaq: TMDX) reported Q2 2026 revenue of $189.9 million, up 21% year over year, with product revenue $111.2 million and service revenue $78.8 million. Net income was $14.7 million, or $0.41 per diluted share. The company raised full-year 2026 revenue guidance (excluding PAD Aviation) to $737 million to $757 million.
6 min read
